MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for mnkd
5.71
+0.07 (1.27%)
Real-time:   9:52AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.65 - 5.74
52 week 3.46 - 11.48
Open 5.65
Vol / Avg. 235,981.00/10.38M
Mkt cap 2.34B
P/E     -
Div/yield     -
EPS -0.44
Shares 409.58M
Beta 1.21
Inst. own 26%
Aug 3, 2015
Q2 2015 Mannkind Corp Earnings Release (Estimated) Add to calendar
Jun 24, 2015
Mannkind Corp at JMP Securities Life Sciences Conference
Jun 10, 2015
Mannkind Corp at Goldman Sachs Healthcare Conference
Jun 3, 2015
Mannkind Corp at Jefferies Global Healthcare Conference
May 21, 2015
Mannkind Corp Annual Shareholders Meeting
May 13, 2015
Mannkind Corp at Bank of America Merrill Lynch Health Care Conference
May 8, 2015
Q1 2015 Mannkind Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 Mannkind Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -32.60% -60.75%
Return on average equity - -
Employees 287 -
CDP Score - -

Address

28903 North Avenue Paine
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company's product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company's Technosphere powders are -based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Officers and directors

Alfred E. Mann Executive Chairman of the Board
Age: 89
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hakan S. Edstrom President, Chief Executive Officer, Chief Operating Officer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew J. Pfeffer CPA Chief Financial Officer, Vice President, IR Contact Officer
Age: 57
Bio & Compensation  - Reuters
Juergen A. Martens Ph.D. Corporate Vice President - Technical Operations, Chief Technical Officer
Age: 59
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kent Kresa Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
James S. Shannon M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters